-transparent.png){kind=logo}
9,10-Anthracenedione derivatives are known to exhibit a quite potent anticancer activity. It has also been reported that these compounds can be effectively employed in both antibacterial and antitrypanosomal therapy. Anthraquinones also exhibit some undesirable side effects, like cardiotoxicity. So many interactions seem to demonstrate that 9,10-anthracenediones strongly interact with a number of biological sites. In this paper we wish to report on the synthesis and the pharmaceutical activity of some newly synthesised derivatives containing the anthraquinone pharmacophore.
Related Publications
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
October 1988,
Journal of medicinal chemistry,
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
June 2003,
Bollettino chimico farmaceutico,
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
April 2007,
European journal of medicinal chemistry,
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
April 1987,
Anti-cancer drug design,
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
May 2012,
Bioorganic & medicinal chemistry letters,
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
July 1988,
Archiv der Pharmazie,
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
March 2006,
Molecules (Basel, Switzerland),
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
May 2014,
European journal of medicinal chemistry,
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
April 2009,
Journal of enzyme inhibition and medicinal chemistry,
M C Cardia, and
M Begala, and
A DeLogu, and
E Maccioni
September 1979,
Journal of medicinal chemistry,
